SRARP and glioblastoma: In addition, SRARP and HSPB7 showed significant copy number gains in only three cancer types, namely cervical cancer, sarcoma, and glioblastoma with gains of 0.15, 0.14, and 0.07 copies, respectively (P < 0.001; Fig. 5).